Compare ARVN & TATT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ARVN | TATT |
|---|---|---|
| Founded | 2015 | 1985 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Aerospace |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 516.2M | 571.4M |
| IPO Year | 2018 | 2002 |
| Metric | ARVN | TATT |
|---|---|---|
| Price | $8.11 | $40.61 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 19 | 6 |
| Target Price | $15.05 | ★ $57.17 |
| AVG Volume (30 Days) | ★ 685.8K | 225.2K |
| Earning Date | 05-04-2026 | 05-18-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 58.84 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $262,600,000.00 | N/A |
| Revenue This Year | N/A | $16.29 |
| Revenue Next Year | N/A | $16.09 |
| P/E Ratio | ★ N/A | $38.61 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $6.06 | $30.36 |
| 52 Week High | $14.22 | $64.50 |
| Indicator | ARVN | TATT |
|---|---|---|
| Relative Strength Index (RSI) | 45.64 | 41.19 |
| Support Level | N/A | $37.39 |
| Resistance Level | $8.90 | $41.91 |
| Average True Range (ATR) | 0.38 | 2.30 |
| MACD | 0.01 | -0.84 |
| Stochastic Oscillator | 18.50 | 16.96 |
Arvinas Inc is a clinical-stage biotechnology company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of therapies that degrade disease-causing proteins. The company is using its PROteolysis TArgeting Chimera, a protein degradation platform, to develop therapeutics designed to harness the body's own natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. Its clinical development program includes various product candidates such as ARV-102, ARV-806, ARV-393, ARV-027, and vepdegestrant, in their different stages of development, being developed to target certain harmful proteins causing oncology and neurology-related diseases.
TAT Technologies Ltd provides solutions and services to the commercial and military aerospace and ground defense industries, focused mainly on three product areas and services: Thermal Management, Power and Actuation, and Maintenance, Repair and Overhaul (MRO). Its product portfolio includes heat exchangers, cooling systems, and mechanical aircraft accessories and systems such as pumps, valves, and turbine power units. Its operating segments are MRO services for aviation components, which derive key revenue, Original equipment manufacturing (OEM) of heat transfer solutions and aviation accessories, MRO services for heat transfer components and OEM of heat transfer solutions, and Overhaul and coating of jet engine components. Geographically, it derives key revenue from the United States.